The Oxford Science Park

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Northbrook House refurbishment announced

10 Jul 2026

The Oxford Science Park (TOSP) has announced plans to refurbish and fit out Northbrook House, a prominent building it acquired last year. The development marks the latest step in the Park’s continued evolution, creating new opportunities for both prospective occupiers and its existing community of growing companies. Comprising 23,088 sq ft, Northbrook House will be transformed into flexible, high-quality laboratory and write-up accommodation,... Read more

How to stay ahead of the talent bottleneck in medtech

26 Jun 2026

The Oxford Science Park is home to some of the UK's most innovative medtech organisations, developing technologies that are transforming patient care, accelerating diagnostics and improving lives worldwide. Yet as companies move closer to clinical, regulatory and commercial milestones, one challenge consistently rises to the top: securing the right talent. Demand for engineers and scientists with expertise across embedded systems,... Read more

The Oxford Science Park celebrates innovation at the 30th Oxfordshire Business Awards

16 Jun 2026

The Oxford Science Park was proud to sponsor the Innovation Award at the 30th anniversary Oxfordshire Business Awards, continuing its longstanding support of one of the county's premier business celebrations which recognises organisations whose ideas, technologies and services are driving progress across Oxfordshire and beyond. The 2026 Innovation Award was won by Greencore Homes, whose pioneering approach to sustainable housebuilding... Read more

Oxford Vacmedix announce successful Phase 1 trial results for cancer

23 Apr 2026

Oxford Vacmedix , a biotech company developing novel immunotherapies to treat cancer, has announced the successful completion of the Phase 1 trial of OVM-200. The primary endpoint for safety has been met as well as the secondary endpoints for immune response and dose selection. In addition, there are early observations of clinical efficacy in NSCLC and in prostate cancer. This Phase 1 clinical trial of OVM-200 is a multicentre, open‑label,... Read more

Vivid Dx: an Oxford spinout racing the clock on sepsis

20 Apr 2026

In the fight against sepsis, speed is everything. Every hour without the right diagnosis increases the risk of death, yet in hospitals around the world, clinicians are still forced to wait days for answers. That stark reality is what drives Vivid Dx, a diagnostics company based at The Oxford Science Park that is transforming how bloodstream infections are detected and treated. The company is built on world-class University of Oxford research,... Read more

News